TLDR A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
The document reports a case of a 24-year-old female patient with alopecia areata totalis (AAT) who experienced a sudden and intense anagen effluvium (rapid hair loss) after testing positive for COVID-19. Despite having complete hair regrowth while using tofacitinib, an oral JAK 1/3 inhibitor, for the last 12 months, the patient's condition worsened after discontinuing the medication due to the COVID-19 infection. The reintroduction of tofacitinib after 14 days did not improve her hair loss even after 3 months. The case suggests that the withdrawal of tofacitinib may lead to persistent anagen effluvium in patients with AA and COVID-19, and the virus may directly affect the hair follicle immune privilege. The exact role of COVID-19 in postinfection hair loss is still unclear, and the authors recommend testing all patients with anagen or telogen effluvium for COVID-19. The document concludes that the continuous use of JAK inhibitors in AA patients who develop COVID-19 infection is controversial and the real effect of the virus on hair follicles needs further investigation.
39 citations,
June 2020 in “Dermatologic Therapy” The COVID-19 pandemic led to an increase in untreated hair diseases and showed the importance of teledermatology.
11 citations,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
14 citations,
August 2018 in “Frontiers in Cellular and Infection Microbiology” Dengue virus can infect human hair follicle cells and may cause hair loss.
99 citations,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
13 citations,
May 2017 in “Dermatologica Sinica” Dengue fever can cause a temporary type of hair loss called telogen effluvium.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
1 citations,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
24 citations,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
